Advanced Enzyme Technologies Limited profit up 14% to Rs 51.15 crore
Key highlights
- Advanced Enzyme Technologies reported September 2026 net profit of Rs 51.15 crore, up 14% from Rs 44.73 crore a year earlier.
- Revenue from operations rose 16% year on year to Rs 214.51 crore in the September 2026 quarter.
- Profit before tax increased to Rs 68.76 crore from Rs 59.54 crore in the year-earlier quarter.
- The company generated Rs 77.20 crore in operating cash flow during the six months ended 30 September 2026.
powered by IRIS

Advanced Enzyme Technologies Limited reported consolidated net profit of Rs 51.15 crore for the quarter ended 30 September 2026, up 14% from Rs 44.73 crore a year earlier. Revenue from operations rose 16% to Rs 214.51 crore, while a Rs 14.30 crore foreign-operation translation gain lifted total comprehensive income to Rs 65.37 crore.
Know Advanced Enzyme Technologies inside out
Results, valuation, peers and who's buying, in one view.
How did Advanced Enzyme Technologies perform in the September quarter?
Advanced Enzyme Technologies reported consolidated net profit attributable to the Group of Rs 51.15 crore for the quarter ended 30 September 2026, compared with Rs 44.73 crore in the quarter ended 30 September 2025. The result followed a Rs 18 lakh share of net loss from its associate, Raywatt Solar Enviro Private Limited, which became an associate with effect from 10 August 2026.
Revenue from operations increased to Rs 214.51 crore from Rs 184.53 crore a year earlier and Rs 191.71 crore in the preceding quarter ended 30 June 2026. Other income was Rs 8.72 crore, below Rs 10.28 crore in the year-earlier quarter and Rs 11.10 crore in the June 2026 quarter, taking total income to Rs 223.23 crore.
Advanced Enzyme Technologies' profit before tax was Rs 68.76 crore, compared with Rs 59.54 crore in the September 2025 quarter and Rs 53.53 crore in the June 2026 quarter. Current tax was Rs 20.16 crore and the deferred-tax credit was Rs 2.57 crore, resulting in total tax expense of Rs 17.59 crore for the September 2026 quarter.
What changed in Advanced Enzyme Technologies' income and costs?
Advanced Enzyme Technologies' total expenses increased to Rs 154.47 crore in the September 2026 quarter from Rs 135.27 crore a year earlier, while revenue from operations increased by Rs 29.98 crore. Cost of materials consumed rose to Rs 59.09 crore from Rs 48.74 crore, and the filing reports the Group in a single segment, manufacturing and sales of enzymes.
The filing does not assign the revenue growth or cost changes to individual enzyme products, customers, territories, volumes or prices. It reports total income of Rs 223.23 crore and profit before tax of Rs 68.76 crore for the September 2026 quarter, compared with Rs 194.81 crore and Rs 59.54 crore, respectively, a year earlier.
For the six months ended 30 September 2026, revenue from operations was Rs 406.22 crore, up from Rs 370.44 crore in the corresponding six months of 2025. Profit before tax rose to Rs 122.28 crore from Rs 114.44 crore, while consolidated net profit attributable to the Group increased to Rs 89.74 crore from Rs 85.17 crore.
Why was Advanced Enzyme Technologies' comprehensive income higher than profit?
Advanced Enzyme Technologies' total comprehensive income exceeded net profit because other comprehensive income was Rs 14.21 crore in the September 2026 quarter. The principal item was a Rs 14.30 crore exchange difference from translating financial statements of foreign operations, partly offset by a Rs 11.9 lakh remeasurement loss on defined-benefit liabilities and a Rs 3 lakh related tax effect.
The September 2026 other comprehensive income contrasts with a negative Rs 1.43 crore in the quarter ended 30 June 2026, when total comprehensive income was Rs 37.16 crore. In the September 2025 quarter, other comprehensive income was Rs 31.21 crore and total comprehensive income was Rs 75.94 crore, despite lower net profit of Rs 44.73 crore.
For the six months ended 30 September 2026, other comprehensive income totalled Rs 12.79 crore, compared with Rs 34.98 crore in the previous corresponding period. As a result, six-month total comprehensive income declined to Rs 102.53 crore from Rs 120.15 crore even though Group net profit increased by Rs 4.57 crore.
Got a follow-up? Ask IRIS
What do Advanced Enzyme Technologies' balance sheet and cash flow show?
Advanced Enzyme Technologies had total assets of Rs 1,905.73 crore at 30 September 2026, compared with Rs 1,838.76 crore at 31 March 2026. Total equity increased to Rs 1,719.90 crore from Rs 1,683.12 crore, while property, plant and equipment rose to Rs 307.69 crore from Rs 275.83 crore.
Capital work-in-progress increased to Rs 83.22 crore at 30 September 2026 from Rs 51.17 crore at 31 March 2026. Inventories rose to Rs 202.71 crore from Rs 177.28 crore, whereas trade receivables declined to Rs 138.03 crore from Rs 145.02 crore over the same period.
Net cash generated from operating activities was Rs 77.20 crore in the six months ended 30 September 2026, compared with Rs 64.71 crore a year earlier. Investing activities generated Rs 44.25 crore, compared with an investing cash outflow of Rs 30.73 crore in the prior period, while financing activities used Rs 72.31 crore.
Cash and cash equivalents stood at Rs 158.76 crore at 30 September 2026, up from Rs 108.76 crore at the start of the financial year. Current liabilities were Rs 117.07 crore, compared with Rs 106.72 crore at 31 March 2026, including Rs 40.60 crore of trade payables to creditors other than micro and small enterprises.
What shareholder actions did Advanced Enzyme Technologies disclose?
Advanced Enzyme Technologies disclosed that its open-market buyback remained open at 30 September 2026. By that date, it had repurchased 1,713,324 equity shares for total cash consideration of Rs 52.08 crore, including Rs 87.8 lakh of buyback-related expenses and transaction costs.
The board approved the buyback on 8 August 2026 at a maximum price of Rs 500 per share and a maximum buyback size of Rs 69.70 crore, excluding transaction costs and taxes. By 30 October 2026, Advanced Enzyme Technologies had repurchased 2,410,906 shares and used Rs 69.70 crore, excluding transaction costs, or 99.99% of the approved buyback size.
The Buyback Committee approved closure of the programme on 30 October 2026. Of the shares bought back by 30 September 2026, 825,028 were extinguished on 7 September and 888,296 were extinguished on 7 October; shares purchased during October are to be extinguished under applicable Companies Act provisions.
Advanced Enzyme Technologies also paid a final dividend of Rs 1.35 per equity share for financial year 2025-26 on 5 August 2026, after shareholder approval on 31 July 2026. Its wholly owned subsidiary Advanced Nutrazyme Private Limited, incorporated on 4 July 2025, is intended to sell and distribute the Nutrition and Wellness product range, although the filing gives no separate September-quarter financial contribution.
Conclusion
Advanced Enzyme Technologies' September-quarter results show higher revenue, profit before tax and consolidated net profit versus the quarter ended 30 September 2025. Revenue reached Rs 214.51 crore and Group net profit reached Rs 51.15 crore, while foreign-operation translation gains of Rs 14.30 crore caused total comprehensive income to rise to Rs 65.37 crore.
The next disclosed matter to watch is the extinguishment of shares repurchased during October 2026 after the Buyback Committee closed the Rs 69.70 crore programme on 30 October 2026. Advanced Enzyme Technologies has also designated Advanced Nutrazyme Private Limited for Nutrition and Wellness sales and distribution, but disclosed no target, timetable or separate financial result for that activity.


